Credit Suisse Group Analysts Give Merck KGaA (MRK) a €93.00 Price Target

Merck KGaA (FRA:MRK) has been assigned a €93.00 ($108.14) price objective by investment analysts at Credit Suisse Group in a report released on Wednesday. The firm presently has a “neutral” rating on the healthcare company’s stock. Credit Suisse Group’s price objective suggests a potential upside of 0.35% from the stock’s current price.

Other research analysts also recently issued research reports about the company. Sanford C. Bernstein set a €105.00 ($122.09) price objective on Merck KGaA and gave the company a “buy” rating in a research note on Tuesday, July 3rd. JPMorgan Chase & Co. set a €90.00 ($104.65) price objective on Merck KGaA and gave the company a “neutral” rating in a research note on Wednesday, October 10th. Berenberg Bank set a €104.00 ($120.93) price objective on Merck KGaA and gave the company a “buy” rating in a research note on Wednesday, July 4th. Societe Generale set a €88.00 ($102.33) price objective on Merck KGaA and gave the company a “neutral” rating in a research note on Wednesday, July 4th. Finally, Commerzbank set a €100.00 ($116.28) price objective on Merck KGaA and gave the company a “buy” rating in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating and nine have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of €98.81 ($114.89).

Shares of FRA MRK opened at €92.68 ($107.77) on Wednesday. Merck KGaA has a 12 month low of €76.60 ($89.07) and a 12 month high of €115.00 ($133.72).

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Recommended Story: What are trading strategies for the 52-week high/low?

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply